Lonza Nominates Stephen Fry as Independent Board Member

Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board of Directors, bringing extensive pharmaceutical industry experience and expertise in organizational transformation.

Chicago Metrowire Staff
Business
Lonza Nominates Stephen Fry as Independent Board Member

The Lonza Board of Directors has announced the nomination of Stephen Fry as an Independent Member of the Board, according to a press release on NewMediaWire. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Fry will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee.

Fry brings deep pharmaceutical industry experience, having spent more than three decades at Eli Lilly and Company. He held a broad range of international, operational and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, Fry led large‑scale organizational transformation, shaped high‑performance cultures and helped navigate the company through significant change. He is also a Member of the Board of Trustees at the University of Indianapolis (US).

Jean-Marc Huet, Chairman of the Board, Lonza, commented: “The Board of Directors extends its warmest congratulations to Stephen for his nomination to the Board. Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level.”

Lonza, the world’s largest contract development and manufacturing organization (CDMO), serves the healthcare industry with a global team of approximately 20,000 colleagues. The company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. More information is available at www.lonza.com.

This nomination is significant as it underscores Lonza’s focus on strengthening its board with expertise in organizational transformation and performance culture, which are critical for the company’s growth and ability to attract top talent in the competitive CDMO sector.

Blockchain Registration

QR Code for Blockchain Registration